Elite Rehab Holtville Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 213 Lightwood Rd Ste 2, Deatsville, AL 36022 Phone: 334-543-4269 Fax: 334-543-4272 |
Mr. William Donald Gill Ii, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 939 Lake Haven Dr, Deatsville, AL 36022 Phone: 251-209-2043 |
News Archive
Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Maybe running comes easy, each stride pleasant and light. Maybe it comes hard, each step a slog to the finish. Either way, the human body is constantly calibrating, making microscopic adjustments to keep us from falling as we weekend-warrior our way to greatness.
Vision RejuvenationTM Victoria, a Canadian leader in advanced cataract and refractive lens exchange surgery has become the first centre in Canada to implant the world's first Light Adjustable Intraocular Lens.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.
› Verified 4 days ago